AI Engines For more Details: Perplexity Kagi Labs You
Replacement Therapy for Hypothyroidism: Thyroxine is the synthetic form of the thyroid hormone thyroxine (T4), which is produced naturally by the thyroid gland. In cases of hypothyroidism, the thyroid gland does not produce sufficient T4, leading to symptoms such as fatigue, weight gain, cold intolerance, dry skin, hair loss, and constipation. Thyroxine medication is prescribed to replace the deficient thyroid hormone and restore normal thyroid function.
Metabolic Regulation: Thyroxine plays a crucial role in regulating metabolism, energy production, and heat generation in the body. It helps maintain normal metabolic rate, protein synthesis, carbohydrate metabolism, lipid metabolism, and overall energy balance. By increasing thyroid hormone levels, thyroxine supplementation can help alleviate symptoms of hypothyroidism and improve metabolic function.
Cardiovascular Effects: Thyroxine has significant effects on the cardiovascular system. It influences heart rate, cardiac output, blood pressure, and lipid levels. In individuals with hypothyroidism, cardiovascular function may be impaired, leading to symptoms such as bradycardia (slow heart rate), reduced cardiac output, and elevated cholesterol levels. Thyroxine therapy can help normalize these cardiovascular parameters and reduce the risk of cardiovascular complications associated with untreated hypothyroidism.
Neurological and Cognitive Function: Thyroxine plays a role in maintaining normal neurological function and cognitive performance. Hypothyroidism can affect brain function and cognition, leading to symptoms such as impaired memory, concentration difficulties, depression, and mood changes. Thyroxine replacement therapy may improve cognitive function and alleviate neuropsychiatric symptoms associated with hypothyroidism.
Bone Health: Thyroid hormones, including thyroxine, play a role in bone metabolism and skeletal development. Hypothyroidism is associated with decreased bone density and an increased risk of osteoporosis and fractures. Thyroxine therapy may help prevent bone loss and maintain bone health in individuals with hypothyroidism by restoring normal thyroid hormone levels.
Reproductive Health: Thyroxine is important for reproductive function and fertility. Hypothyroidism can disrupt menstrual cycles, impair fertility, and increase the risk of pregnancy complications such as miscarriage, preterm birth, and fetal growth restriction. Thyroxine replacement therapy may restore normal menstrual function, improve fertility, and reduce the risk of adverse pregnancy outcomes in women with hypothyroidism.
Monitoring and Dosage Adjustment: Thyroxine therapy requires careful monitoring of thyroid hormone levels through blood tests, typically thyroid-stimulating hormone (TSH) levels. The dosage of thyroxine medication may need to be adjusted periodically based on TSH levels and clinical response to treatment. It's important for patients to follow their healthcare provider's recommendations regarding dosage, timing of medication administration, and regular follow-up appointments.
Adverse Effects: While thyroxine replacement therapy is generally well-tolerated, excessive thyroxine dosage can lead to symptoms of hyperthyroidism, including palpitations, tremors, anxiety, insomnia, weight loss, and heat intolerance. Patients should report any unusual symptoms to their healthcare provider promptly, and dosage adjustments may be necessary to optimize treatment efficacy and minimize adverse effects.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.6 | 0.6 | |
| ADHD | 1 | 0.3 | 2.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
| Allergies | 0.6 | 0.3 | 1 |
| Allergy to milk products | 0.6 | 0.3 | 1 |
| Alzheimer's disease | 0.8 | 3.6 | -3.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.9 | |
| Ankylosing spondylitis | 0.6 | 0.6 | 0 |
| Anorexia Nervosa | 1.4 | -1.4 | |
| Antiphospholipid syndrome (APS) | 0.6 | 0.3 | 1 |
| Asthma | 1.1 | 0.8 | 0.38 |
| Atherosclerosis | 0.3 | 1.1 | -2.67 |
| Atrial fibrillation | 1.2 | 1.2 | 0 |
| Autism | 1.7 | 2.9 | -0.71 |
| Autoimmune Disease | 0.5 | -0.5 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Bipolar Disorder | 0.6 | 0.8 | -0.33 |
| Brain Trauma | 0.8 | -0.8 | |
| Cancer (General) | 0.6 | -0.6 | |
| Carcinoma | 0.6 | 0.3 | 1 |
| Celiac Disease | 0.9 | 0.9 | 0 |
| Cerebral Palsy | 0.3 | 0.8 | -1.67 |
| Chronic Fatigue Syndrome | 0.5 | 1.9 | -2.8 |
| Chronic Kidney Disease | 0.9 | 2 | -1.22 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 1.1 | -2.67 |
| Coagulation / Micro clot triggering bacteria | 0.5 | -0.5 | |
| Cognitive Function | 0.8 | 0.5 | 0.6 |
| Colorectal Cancer | 0.8 | 1.1 | -0.38 |
| Constipation | 0.6 | 0.5 | 0.2 |
| Coronary artery disease | 0.3 | 1.7 | -4.67 |
| COVID-19 | 0.5 | 3.4 | -5.8 |
| Crohn's Disease | 1.6 | 2.6 | -0.63 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 0.8 | 0.8 | 0 |
| Depression | 2.5 | 4.7 | -0.88 |
| Endometriosis | 0.6 | 1.1 | -0.83 |
| Epilepsy | 0.3 | 0.3 | 0 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.5 | 1.1 | -1.2 |
| Functional constipation / chronic idiopathic constipation | 1.5 | 1.1 | 0.36 |
| gallstone disease (gsd) | 0.5 | -0.5 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 0.6 | 0.6 | 0 |
| Gout | 0.3 | 0.3 | 0 |
| Graves' disease | 0.3 | 1.1 | -2.67 |
| Gulf War Syndrome | 0.3 | 0.3 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.8 | 0.9 | -0.13 |
| Heart Failure | 1.8 | 1.1 | 0.64 |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hyperglycemia | 0.3 | -0.3 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.6 | 2.6 | -3.33 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.3 | 1.3 | -3.33 |
| Inflammatory Bowel Disease | 1.5 | 3 | -1 |
| Insomnia | 0.6 | 1.4 | -1.33 |
| Intelligence | 0.8 | 0.8 | |
| Intracranial aneurysms | 0.3 | 0.3 | 0 |
| Irritable Bowel Syndrome | 0.8 | 1.6 | -1 |
| ischemic stroke | 0.3 | 1.1 | -2.67 |
| Liver Cirrhosis | 2.3 | 1.4 | 0.64 |
| Long COVID | 1.5 | 2.6 | -0.73 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.3 | -0.3 | |
| ME/CFS with IBS | 0.9 | -0.9 | |
| ME/CFS without IBS | 0.3 | -0.3 | |
| Menopause | 0.5 | -0.5 | |
| Metabolic Syndrome | 1.5 | 2.2 | -0.47 |
| Mood Disorders | 2.5 | 3.5 | -0.4 |
| Multiple Sclerosis | 0.3 | 2.3 | -6.67 |
| Multiple system atrophy (MSA) | 0.6 | 0.6 | |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 1.7 | -1.7 | |
| Neuropathy (all types) | 0.5 | -0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.1 | 2 | -0.82 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 2.3 | 2 | 0.15 |
| obsessive-compulsive disorder | 1.4 | 0.9 | 0.56 |
| Osteoarthritis | 0.5 | 0.3 | 0.67 |
| Osteoporosis | 0.8 | 0.3 | 1.67 |
| Parkinson's Disease | 2 | 3.5 | -0.75 |
| Polycystic ovary syndrome | 1.1 | 1.1 | 0 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| primary biliary cholangitis | 0.2 | -0.2 | |
| Primary sclerosing cholangitis | 0.3 | 0.3 | 0 |
| Psoriasis | 1.7 | -1.7 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.7 | 1.7 | 0 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 1.3 | 1.4 | -0.08 |
| scoliosis | 0.3 | 0.9 | -2 |
| Sjögren syndrome | 0.8 | -0.8 | |
| Sleep Apnea | 0.6 | 1.1 | -0.83 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 0.8 | 1.1 | -0.38 |
| Systemic Lupus Erythematosus | 0.9 | 1.4 | -0.56 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 0.9 | 1.1 | -0.22 |
| Type 2 Diabetes | 1.7 | 1.3 | 0.31 |
| Ulcerative colitis | 0.6 | 2.8 | -3.67 |
| Unhealthy Ageing | 1.5 | 1.4 | 0.07 |
| Vitiligo | 0.6 | 0.6 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
